



## Acceleron to Participate in Two Healthcare Investor Conferences in May

May 2, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in May.

### Conference Details:

Event: Deutsche Bank 43<sup>rd</sup> Annual Health Care Conference

Date: Tuesday, May 8, 2018

Location: Boston, MA

Event: UBS Global Healthcare Conference

Date/Time: Tuesday, May 22, 2018 at 1:30 p.m. EDT

Location: New York, NY

A live audio webcast for the UBS conference will be available on the Investors/Media page of the Company's website at [www.acceleronpharma.com](http://www.acceleronpharma.com). A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

### About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.

For more information, please visit [www.acceleronpharma.com/](http://www.acceleronpharma.com/). Follow Acceleron on Social Media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180502005192/en/>

Source: Acceleron Pharma

Acceleron Pharma Inc.

Todd James, IRC, 617-649-9393

Vice President, Investor Relations and Corporate Communications

or

Candice Ellis, 617-649-9226

Manager, Investor Relations and Corporate Communications

or

Media:

BMC Communications

Brad Miles, 646-513-3125